Rhythm Pharmaceuticals Inc
Research Rhythm Pharmaceuticals Inc (RYTM) on Bullrun: market cap USD 7.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRYTM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 7.78B
- Financial periodQ2 2026
- RevenueUSD 71.26M
- Net income-USD 49.30M
- Free cash flow-USD 9.15M
- Gross margin87.5%
Valuation Snapshot
latest market cap is USD 7.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 189.76M | -USD 196.54K | -USD 116.63M | 89.7% | -3.11 | USD 54.30M | USD 108.18M | USD 139.07M |
| FY2024 | USD 130.13M | -USD 260.60K | -USD 113.88M | 89.7% | -4.34 | USD 89.14M | USD 109.81M | USD 21.73M |
| FY2023 | USD 77.43M | -USD 184.68K | -USD 136.20M | 88.0% | -3.2 | USD 60.08M | USD 106.14M | USD 169.76M |
| FY2022 | USD 23.64M | -USD 181.12K | -USD 173.71M | 91.0% | -3.47 | USD 127.68M | USD 72.96M | USD 264.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 7.78B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.19B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.49B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.72B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.64B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 501.83M | n/a | n/a | n/a |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rhythm Pharmaceuticals Inc's market cap?
Rhythm Pharmaceuticals Inc's market capitalization is USD 7.78B.
What does Rhythm Pharmaceuticals Inc do?
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.